Blue Wolf Capital to Create New CDMO Platform
Deal News | Feb 20, 2025 | MTS Health Partners LP
Blue Wolf Capital, a private equity firm, is establishing a new contract development and manufacturing organization (CDMO) platform in Europe. This platform will merge seven facilities acquired from Recipharm, located in Sweden, France, and Spain, with those of Synerlab, a CDMO headquartered in France, pending regulatory clearance. The combined entity aims to lead in oral solid, semi-solid, and liquid dosage pharmaceutical products while expanding its expertise in niche processes like freeze drying. Experienced executives will lead the new organization, including Bruce Vielle, CEO of Synerlab. Blue Wolf Capital plans further growth and expansion across Europe, with a corporate name announcement due by year's end. The Synerlab transaction will close in Q4 2024.
Sectors
- Pharmaceutical Manufacturing
- Private Equity
Geography
- Europe – The new CDMO platform will be based in Europe, with facilities in Sweden, France, and Spain, highlighting its focus on the European pharmaceutical market.
- United Kingdom – The combined CDMO platform will be headquartered in the UK, centralizing management and operations.
Industry
- Pharmaceutical Manufacturing – The article discusses the establishment of a new CDMO platform focused on pharmaceutical production, involving multiple dosage forms and specialized processes.
- Private Equity – Blue Wolf Capital, a private equity firm, is financing and strategically guiding the creation of a new European CDMO platform.
Financials
- Not Disclosed – The terms of the transaction were not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Blue Wolf Capital Partners LLC | Acquirer/Private Equity Firm | Company | A private equity firm focusing on value investments in healthcare and industrial sectors. |
| Recipharm | Vendor | Company | A pharmaceutical CDMO company from which seven manufacturing sites were acquired. |
| Synerlab | Target Company | Company | A CDMO headquartered in France with expertise in multiple dosage forms and specialized pharmaceutical processes. |
| Bruce Vielle | Chief Executive Officer | Person | CEO of Synerlab and expected future CEO of the new CDMO platform. |
| Peter Kruger | Chief Commercial Officer | Person | Previously Chief Business Officer for the facilities acquired from Recipharm. |
| Rich Fenton | Chief Financial Officer | Person | Former CFO for TFL Group and Norgren Europe. |
| Steve Leonard | Chief Operating Officer | Person | Previously VP of Global Operations and Supply Chain at Integra Life Sciences. |
| Saurabh Singh | Chief Strategy Officer | Person | Former VP of Strategy & Business Development for Avet Pharmaceuticals. |
| Amy Mort | Group Head of HR | Person | Handled HR for the facilities acquired from Recipharm. |
| William Marth | Board Member | Person | President and COO of Resilience, former CEO of AMRI, with extensive industry experience. |
| George Svokos | Board Member | Person | President and CEO of Avet Pharmaceuticals, former COO and CCO at AMRI. |
| Shashank Patel | Principal | Person | Principal at Blue Wolf Capital, overseeing the CDMO platform initiative. |
| MTS Health Partners LP | Advisor | Company | Advisory partner for Blue Wolf Capital in the transaction. |